Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhPTH(1-84) for symptomatic chronic hypoparathyroidism
NL-OMON55679Phase 3Completed
- Sponsor
- Takeda
- Start
- Sep 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic hypoparathyroidism comparing rhPTH(1-84) plus standard therapy with Placebo plus standard therapy (2 arms). Started Sep 2018; status: completed.
02
Drugs
parathyroid hormone 1-84
03
Conditions
chronic hypoparathyroidism
Beyond the preview
Go deeper on NL-OMON55679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55679.